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Stormorken syndrome is a rare autosomal dominant disease that is characterized by a
complex phenotype that includes tubular aggregate myopathy (TAM), bleeding diathesis,
hyposplenism, mild hypocalcemia and additional features, such as miosis and a mild
intellectual disability (dyslexia). Stormorken syndrome is caused by autosomal dominant
mutations in the STIM1 gene, which encodes an endoplasmic reticulum Ca2+ sensor.
Here, we describe the clinical and molecular aspects of a 21-year-old Italian female with
Stormorken syndrome. The STIM1 gene sequence identified a c.910C > T transition
in a STIM1 allele (p.R304W). The p.R304W mutation is a common mutation that is
responsible for Stormorken syndrome and is hypothesized to cause a gain of function
action associated with a rise in Ca2+ levels. A review of published STIM1 mutations
(n = 50) and reported Stormorken patients (n = 11) indicated a genotype-phenotype
correlation with mutations in a coiled coil cytoplasmic domain associated with complete
Stormorken syndrome, and other pathological variants outside this region were more
often linked to an incomplete phenotype. Our study describes the first Italian patient with
Stormorken syndrome, contributes to the genotype/phenotype correlation and highlights
the possibility of directly investigating the p.R304W mutation in the presence of a typical
phenotype.
Highlights
- Stormorken syndrome is a rare autosomal dominant disease.
- Stormoken syndrome is caused by autosomal dominant mutations in the STIM1 gene.
- We present the features of a 21-year-old Italian female with Stormorken syndrome.
- Our review of published STIM1mutations suggests a genotype-phenotype correlation.
- The p.R304W mutation should be investigated in the presence of a typical phenotype.
Keywords: stormorken syndrome, STIM1, tubular aggregate myopathy, muscle, myopathy
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INTRODUCTION
Stormorken syndrome is a rare disorder (OMIM: #185070) with
a complex phenotype comprising muscle fatigue associated with
tubular aggregatemyopathy (TAM), asplenia, a bleeding diathesis
associated with thrombocytopenia and/or thrombocytopathy,
miosis, and additional features, including ichthyosis, short
stature, aminimal cognitive impairment (dyslexia) andmigraines
(1–6).
TAM is a rare disorder in which tubular aggregates
are the main pathological hallmarks in muscle tissue (7).
Tubular aggregates may also be found in congenital myasthenic
syndromes (8) and in other hereditary myopathies as an
accompanying feature (9). Tubular aggregates are composed
of tubules derived from the sarcoplasmic reticulum oriented
in regular arrays (10). A “pure” form of TAM, which is
clinically characterized by cramps, myalgias, muscle stiffness and,
eventually, proximal muscle weakness, has been described. TAM
may be sporadic or inherited as an autosomal dominant trait (9).
Heterozygous dominant mutations in the STIM1 gene
(chromosome 11p15) have been determined to be causative of
Stormorken syndrome (6). The STIM1 gene encodes the major
Ca2+ sensor of the endoplasmic reticulum (ER), called “stromal
interaction molecule 1” (STIM1) (11, 12).
STIM1 is a conserved protein in which the N-terminal
(luminal) region is separated from the C-terminal (cytoplasmic)
domain by a single transmembrane domain. The C-terminal
domain harbors three coiled coil (CC) domains, and the N-
terminal region harbors two EF-hand domains that act as
calcium sensors within the ER. Depletion of calcium from the
endoplasmic reticulum causes the dissociation of Ca2+ from the
STIM1 luminal domain, which in turn, induces the generation
of higher-order STIM1 oligomers. These changes in the STIM1
conformation were proposed to lead to its migration toward
the so-called “puncta regions,” which are discrete cell sites
originating from the endoplasmic reticulum-plasma membrane
(ER–PM) apposition. In these sites, STIM1 oligomers interact
with ORAI1, a cytoplasmic membrane Ca2+ release-activated
Ca2+ (CRAC) channel, causing the ORAI1 channel to open, as
well as stimulating store-operated calcium entry (SOCE) (11, 12).
STIM1 protein oligomerization may be constitutively activated
by STIM1 gene mutations (such as R304W and L251S) located
in the region encoding the cytosolic domain. These events lead
to STIM1 puncta development and Ca2+ influx through CRAC
channels. These mutations lead to a STIM1 gain of function and
can mimic the activated conformations of STIM1 (1, 12, 13). In
addition to STIM1, TAM may be caused by mutations in ORAI1
(1, 14).
The most common STIM1 mutation (c.910C>T, p.R304W)
described in subjects affected by classic (complete) Stormorken
syndrome involves the first CC domain (1, 2, 6). However,
several heterozygous mutations have been described in the EF-
hand domain of STIM1, leading to incomplete phenotypes,
such as non-syndromic tubular aggregate myopathies (TAM)
with miosis and York platelet syndrome (YPS) (15). There
is marked diversity in the neuromuscular features of subjects
with mutations in the EF-hand vs. those with mutations in
the CC domain. In particular, subjects with a mutation in the
EF-hand have an earlier onset of neuromuscular symptoms and
higher prevalence of myalgia, contractures, ophthalmoplegia,
and progressive weakness than those with mutations in the CC
domain (4). Finally, recessive mutations in STIM1 have been
described to be associated with immunodeficiency and Kaposi’s
sarcoma (16–18). Taken together, these data suggest a possible
genotype–phenotype correlation associated with the site of the
mutation.
Here, we describe a novel case of a 21-year-old Italian patient
with the p.R304W STIM1 mutation who presented with the
classic Stormorken phenotype.
MATERIALS AND METHODS
The subject of this observational study was evaluated at
the IRCCS Foundation Ca’ Granda Maggiore Hospital was
performed according to the Declaration of Helsinki. Written
informed consent was obtained from the participant for
the publication of this case report. A complete neurological
examination was performed, and signs of Stormorken syndrome
were examined in the proband. The study was extended to the
parents.
The blood tests performed included evaluation of the full
blood count, liver function tests, inflammatory markers, serum
electrolytes, markers of renal function, creatine phosphokinase
(CK), thyroid stimulating hormone (TSH), parathyroid hormone
(PTH), and coagulation.
To assess whether clinical and biochemical features were
associated with the involvement of the nerves and muscles,
neurophysiological studies were conducted, including a nerve
conduction study (NCS) and needle electromyography (EMG).
A standard brain MRI and muscle MRI were performed
with 1.5 Tesla equipment (Philips Achieva, Eindhoven, the
Netherlands). Non-contrast axial images were generated using
T1-TSE (turbo spin echo) sequences to detect fatty replacement.
Short tau inversion recovery (STIR) sequences were acquired on
the axial plane to determine muscle edema.
A biopsy of the patient’s left biceps muscle was performed,
and 10µm cryostatic cross sections were processed according
to standard histological/histochemical techniques (Gomori
Trichrome and Hematoxylin and eosin stain) (19). Enzymatic
activity was demonstrated by ATPASE (9.4, 4.6, 4.3), COX,
succinic dehydrogenase (SDH) and double staining for COX and
SDH, acid phosphatase, NADH, Oil Red O, PAS, myoadenylate
deaminase, and myophosphorylase (20). Moreover, thin sections
were evaluated with an electron microscope (EM 109 Zeiss)
(20, 21).
To isolate genomic DNA, peripheral blood was taken from the
proband and her family members. We used previously described
primers (2) and Touch Down 64–54 PCR. The PCR products
were purified by exonuclease I and alkaline phosphatase (Thermo
Scientific) and were directly sequenced on both strands using an
ABI 3130 Genetic analyzer with Big Dye Terminator chemistry.
Sequence alignments were performed using the SeqScape v2.5
software (Applied Biosystems). After detecting the mutation in
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TABLE 2 | Clinical features of STIM1 mutations CC and EF.
CC (n = 19) EF (n = 30)
Gender, M (%) 58 53
Age of onset (%)
Asymptomatic 0 3 (10)
Congenital 2 (10) 3 (10)
Childhood/Adolescence 6 (31) 22 (73)
Adulthood 4 (21) 2 (7)
Myalgia, yes (%) 8 (42) 11 (37)
Muscular weakness, yes (%) 13 (68) 24 (80)
Contractures, yes (%) 3 (16) 16 (53)
Ambulant, yes (%) 6 (32) 25 (83)
Miosis, yes (%) 14 (73) 5 (17)
Ophtalmoplegia, yes (%) 2 (10) 11 (37)
Thrombocytopenia/platelets dysfunction, yes (%) 15 (79) 6 (20)
Asplenia/hyposplenia, yes (%) 10 (53) 4 (13)
Cardiac dysfunction, yes (%) 0 (0) 3 (10)
Respiratory dysfunction, yes (%) 0 (0) 4 (13)
Hypocalcemia, yes (%) 8 (42) 3 (10)
the proband, the genomic DNA of all family members was
screened for variant segregation by sequencing exon 7 in the
STIM1 gene.
To estimate the mutation frequency, clinical presentation and
genotype/phenotype correlation of Stormorken syndrome, we
performed a comprehensive literature search in MEDLINE from
1985 until September 2017 and retrieved 11 studies reporting this
condition. The key words utilized for the database-search were
the following: “STIM1,” “Stormorken syndrome,” and “Tubular
aggregate myopathy.” The collected data included the clinical
phenotype, gender of all patients, age of onset, laboratory, and
histological data and genotype. We then compared these features
between two main groups of patients: those who harbored
mutations within the CC-hand domain (n = 19) and those
who harbored mutations within the EF-hand domain (n = 30;
Tables 1, 2).
RESULTS
Clinical Findings: History and Clinical
Examination
A 21-year-old female of Italian origin was referred to our
Neuromuscular Center because of chronic CK elevation that
ranged from 439 to 2350 UI/l and mild symptoms. She only
complained of episodes of diffuse myalgia during fever episodes.
Because of these symptoms, she was admitted to the emergency
department three times over the last three years, during which
she underwent blood tests, urinalyses, chest radiographs, arterial
blood gas measurements, electrocardiography, and abdominal
and cardiac ultrasounds. High CK serum levels, low blood
platelet counts, a low calcium serum concentration (corrected for
albumin level) and a reduced spleen size were detected.
Her past medical history revealed several associated clinical
conditions, including the following: congenital bilateral miosis
FIGURE 1 | Morphological and ophthalmological findings in a 21-year-old
Italian female with Stormorken syndrome. (A) Close-up photo of the patient’s
eyes showing bilateral and symmetric miosis. (B) Photo of the patient’s feet
showing partial syndactyly of the second and third toes.
without eye pain, an increased ocular tone or other signs of
retinopathy; a diagnosis of idiopathic thrombocytopenic purpura
(ITP) when she was 6 years old with several episodes of mucosal
bleeding, such as epistaxis and menorrhagia. A diagnosis of
dyslexia wasmade in the same year; ten years later, the patient was
diagnosed with an episode of autoimmune thyroiditis associated
with antithyroglobulin antibodies. Finally, in the last year, a
functional platelet defect characterized by impaired platelet
activation and secretion after stimulation with ADP, collagen and
TRAP (Thrombin receptor-activating peptides) was discovered.
A clinical examination revealed a short stature (148 cm)
without dysmorphic signs. The patient appeared alert and
oriented to person, place, and time. The clinical examination
of the cranial nerves revealed bilateral, symmetric miosis
(Figure 1A) and a poor response to a light stimulus without
diplopia or ptosis. Examination of the ocular extrinsic
musculature revealed no defects. She presented with very mild
symmetrical muscle weakness with predominant impairment
of the proximal lower limbs (MRC score 5-/5) and an even
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FIGURE 2 | (A) Axial T1 image at the pelvis showing atrophy and moderate fatty replacement involving the gluteus maximus, particularly on the right side (black
arrow); (B) axial T1 MR image at the level of the calf showing the relative sparing of the muscles with only moderate involvement of the gastrocnemii lateralis (dotted
white arrow); (C,D) coronal and axial T1 MR images at the level of the cingular girdle showing mild fatty infiltration in the subscapularis muscles.
milder involvement of the axial muscles and upper limbs. No
other abnormalities of motor or sensory functions were detected
except for a slight postural tremor in the upper arms when the
arms were outstretched. No abnormalities in gait, posture or
coordination were detected. She was independently ambulant,
even if she reported exercise intolerance. Partial syndactyly of the
second and third toes (Figure 1B) was detected when the lower
limbs were examined.
Blood tests revealed elevated CK serum levels (898 U/L), low
platelet counts (87000/mm3), hypocalcemia (2.03 mmol/L) with
normal phosphatemia and a serum PTH concentration of 9.2
pg/mL, which was inappropriately low given her low calcium
level. All of the other laboratory findings were normal.
Electroneurography did not reveal alterations in the
amplitude of the compound muscle action potentials or sensory
nerve action potentials. Electromyography did not reveal
pathological findings.
Brain and brainstemMRI (without contrast medium) showed
no abnormal focal areas of altered signal intensity in the
cerebral hemispheres, brainstem, or cerebellum. Lower limb MR
imaging revealed a mild fatty replacement within the gluteus
maximus muscles, especially in the right gluteus maximus
(Figure 2A). In the leg, the gastrocnemius lateralis was slightly
affected by fatty replacement (Figure 2B). There was sparing
of the tibialis anterior and posterior muscles (Figure 2B). T1-
weighted MR imaging of the upper limb and cingular girdle
demonstrated some alterations that were characterized by mild
fatty infiltration in the subscapularis and pectoralis major
(Figures 2C,D). The masticatory muscles (temporal, masseter
and lateral pterygoid) were normal. In the upper limbs, the
triceps and biceps brachii were spared. No bright signal was
observed on the STIR sequence, suggesting the absence of areas
with inflammatory edema. Compared to other reported cases,
only mild changes were described. Moreover, in STIM1 disease, a
peculiar involvement of the flexor halluces longus, which was not
present in this case, has been reported.
A histological examination of the biopsy of the left biceps
(Figures 3A–F) revealed the presence of diameter variations
of type 1 and 2 fibers. We also detected multiple basophilic
cytoplasmic inclusions inmanymuscle fibers that were consistent
with tubular aggregates (TA; Figure 3A). No signs of necrosis
or inflammation were observed. Slightly augmented internalized
nuclei, few fiber splittings and type 2 fiber atrophy were observed.
A histochemical examination including the NADH reaction
showed many cytoplasmic dark stained areas (Figure 3B). The
areas positive for NDAH were negative for SDH, supporting
an endoplasmic reticulum origin (Figure 3F). Moreover, the
histochemical analysis detected small accumulation of PAS-
positivematerial (Figure 3E) In conclusion, the histopathological
data obtained from examining the biceps sample revealed
significant pathological muscular involvement indicative of
tubular aggregate myopathy.
The electron microscopy analysis revealed the presence of
tubular aggregates constituting single-walled (250 nm diameter)
membrane tubules (Figures 3C,D).
STIM1 gene analysis in our patient using Sanger direct
sequencing showed a de novo heterozygous missense mutation,
a c.910C > T transition (NM_003156.3; rs483352867), which
caused a p.R304W amino acid substitution in the protein and
affected a highly conserved cytoplasmic CC domain (Figure 4).
This protein alteration, which has already been reported in the
literature in patients with Stormorken syndrome (6), impaired
the conformation of the STIM1 inhibitory helix by unlocking the
inhibitory state of STIM1 (2) and was able to stimulate the CRAC
channel. This mutation was absent in the unaffected relatives
(Figure 4).
Correlation Between the Genotype and
Phenotype in Stormorken Syndrome: A
Review of the Literature
We conducted a review of published STIM1 (dominant) gain of
function mutations (n = 50). Patients were grouped according
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FIGURE 3 | Histological, histochemical and ultrastructural findings. (A) A Modified Gomori Trichrome stain (40X) showing tubular aggregates and a lack of tubular
aggregates. (B) NADH (40X) reaction showing many cytoplasmic dark stained areas. (C,D) (C: 12000X) (D: 20000X) EM. Subsarcolemmal evidence of tubular
aggregates (asterisks). (E) small accumulations of PAS positive material was detected in some fibers. (F) SDH staining showed no accumulations even in the
described vacuolated areas. Scale bar: (A,B) 12.5µm (C) 0.42µm (D) 0.25µm (E, F) 25µm.
to their STIM1 genotype: 19/50 harbored mutations within
the CC-hand domain and 30/50 patients harbored mutations
within the EF-hand domain (Table 1). One patient harbored a
mutation within the CTID domain (24). All reported classic
Stormorken patients harbored a common mutation in p.R304W
in a coiled coil domain. Moreover, when these genotypic groups
were compared, CC-hand domain mutations were found to be
associated with a more complete extra-muscular involvement
(presence of miosis, thrombocytopenia/platelet dysfunction,
asplenia or hyposplenia and hypocalcemia) than those harboring
EF-hand domain mutations. These data suggest a genotype-
phenotype correlation between mutations within the coiled coil
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FIGURE 4 | DNA sequencing analysis of the patient and her parents
demonstrating a de novo heterozygous transition in the patient with the
common c.910C>T mutation in STIM1.
domain that is associated with complete Stormorken syndrome,
whereas mutations outside of this region more often present with
an incomplete phenotype.
DISCUSSION
Stormorken syndrome, the only recognized syndrome
combining myopathy and congenital hypo/asplenia, was
reported in 1985 by Stormorken et al. in a family from Norway
that had an autosomal dominant transmission. Stormorken
syndrome is a rare condition in which a combination of
hypocalcemia, hematological abnormalities (including asplenia,
anemia, thrombocytopenia, or thrombocytosis), TAM and
other features, such as short stature, miosis, migraine, dyslexia,
and ichthyosis, may be observed (5). Recent reports have
described that a wide range of STIM1 mutations are the cause of
Stormorken syndrome: the most common mutation, p.R304W,
involves the coiled coil domain and appears to lead to a gain of
function of the STIM1 protein (1, 2, 6).
Our patient who was of Italian origin presented with the
clinical features of Stormorken syndrome, including myopathy,
miosis, bleeding tendency, thrombocytopenia, hyposplenia, and
dyslexia.
Muscular involvement in Stormorken syndrome consists
of a gradually progressive muscle weakness, primarily of the
proximal lower limb, in association with exercise intolerance,
joint contractures, ophthalmoparesis without diplopia or
ptosis, and elevated CK levels (15). Our patient showed a
phenotype consistent with the previously described phenotype
and presented with increased CK, mild muscle weakness,
exercise intolerance and sporadic myalgia. In general, the CK
serum levels reported in the literature show very high variability
among cases, independent of the severity of the symptoms or the
localization of the mutation within the STIM1 gene. It may be
possible that other unrecognized genetic and epigenetic factors
can act as modifiers of the clinical phenotype by altering calcium
homeostasis, stabilizing muscular cell membranes or influencing
cellular stress-response pathways. Further research should be
performed to clarify this high variability.
Muscle imaging was performed in five patients with STIM1-
associated TAM (28). In the lower limb, fatty substitution of the
obturator and gluteal muscles was found in early disease stages.
Similar findings were found in the sartorius muscle.
In later stages, general alterations of the anterior and posterior
thigh were found, with relative preservation of the adductor
longus, gracilis, and the short head of the biceps femoris.
In the lower leg, alterations of the posterior compartment
(gastrocnemii and soleus) were present. In the upper limb, the
subscapularis muscle was consistently involved and the trapezius
was preserved. However, only mild changes were observed in our
case.
Muscle biopsy agreed with the histological and electron
microscopy findings of TAM.
Sanger analysis of the patient’s genome revealed the common
p.R304Wmutation.
Previous functional analyses suggested that this mutation
causes constitutive STIM1 activation, with a consequent
dysregulation of intracellular Ca2+ homeostasis and an increase
in the basal Ca2+ levels in patient’s derived fibroblasts and
STIM1-R304W overexpressing HEK 293T cells (2). Therefore,
the administration of SOCE inhibitors, such as resveratrol, could
be a possible therapeutic approach (29). Resveratrol is a natural
phytoalexin that is used as a nutrition supplement due to its
health-promoting benefits and is an inhibitor of store-operated
calcium entry (SOCE) (29). In fact, it has been demonstrated
that resveratrol inhibits the ERK1/2 activation triggered by Ca²+
store depletion. Since resveratrol is already used in humans, it
can be transferred to the clinic. Indeed, further knowledge of the
molecular mechanism underlying this inhibition will allow the
effective design of therapies that include resveratrol or related
stilbenoids (29).
In a patient with hypocalcemia, the use of calcitriol was shown
to have a significantly ameliorated neuromuscular function (30),
but these findings were not investigated further.
Mutations in STIM1 are believed to cause either TAM or
Stormorken syndrome in correlation with the domain that the
mutation affects. To clarify the correlation between the STIM1
genotype and phenotype, we reported comprehensive clinical
and genetic features from 50 patients described in the literature
with STIM1 dominant gain of function mutations in the EF-
hand or CC domains. Our findings suggest that extra-muscular
features, such as hypocalcemia, thrombocytopenia, platelet
defect and hyposplenia or asplenia, are related to mutations
within the coiled domain of the STIM1 protein. Moreover, the
neuromuscular phenotype was substantially different according
to which STIM1 protein domain was affected; subjects with
EF-region domain mutations presented with a more severe
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neuromuscular dysfunction that was characterized by progressive
hyposthenia and contractures and earlier onset than patients
harboring mutations in the CC region domain, in which neither
weakness nor contractures was reported. In fact, mutations in the
EF-hands constitutively activate STIM1, leading to permanent,
store-independent calcium entry. By contrast, mutations in
the STIM1 CC domains confer a gain of function that is
only revealed by store depletion. Therefore, tissues relying on
store-operated calcium entry for differentiation and function
might be preferentially affected by this mutation (1). This
mechanistic difference might explain the genotype-phenotype
correlation.
Our study is the first report of an Italian patient with
Stormorken syndrome and confirms the association between the
most common STIM1 gain of function mutation (c.910C>T,
p.R304W) within the CC domain and the majority of the clinical
features already described in Stormorken syndrome.
Our data strengthen this genotype/phenotype correlation
between the STIM1 p.R304W mutation and points to the
possibility of directly investigating this mutation in the presence
of a typical phenotype.
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